Prevalence and antimicrobial susceptibility pattern of extended-spectrum beta-lactamase-producing enterobacteriaceae in the United Arab Emirates

Medical Principles and Practice

Volumn 17, Issue 1, 2008, Pages 32-36

  Al Zarouni, Mansour ^a   Senok, Abiola ^b   Rashid, Fatima ^a   Al Jesmi, Shaikha Mohammed ^a   Panigrahi, Debadatta ^b  

^a Al Qassimi Hospital   (United Arab Emirates)

^b UNIVERSITY OF SHARJAH   (United Arab Emirates)

Author keywords

Antimicrobial resistance; Enterobacteriaceae; Escherichia coli; Extended spectrum lactamase; Klebsiella pneumoniae

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; AZTREONAM; BETA LACTAMASE; CARBAPENEM; CEFOTETAN; CEPHALOSPORIN; CIPROFLOXACIN; CLAVULANIC ACID; GENTAMICIN; IMIPENEM; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM DETECTION; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; BLOOD; CATHETER; CEREBROSPINAL FLUID; CONTROLLED STUDY; ENDOTRACHEAL TUBE; ENTEROBACTERIACEAE; ESCHERICHIA COLI; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; NONHUMAN; PHENOTYPE; PREVALENCE; PUS; UMBILICAL CORD; UNITED ARAB EMIRATES; URINE;

BETA-LACTAM RESISTANCE; BETA-LACTAMASES; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; ESCHERICHIA COLI; HUMANS; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS; PREVALENCE; UNITED ARAB EMIRATES;

EID: 36749013015     PISSN: 10117571     EISSN: None     Source Type: Journal    
DOI: 10.1159/000109587     Document Type: Article

References (27)

1. Paterson DL, Bonomo RA: Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev 2005;18:657-686.
2. Bradford PA: Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev 2001;14:933-951.
3. Bonnet R: Growing group of extended-spectrum beta-lactamases: the CTX-M enzymes. Microb Agents Chemother 2004;48:1-14.
4. Mugnaioli C, Luzzaro F, De LF, Brigante G, Perilli M, Amicosante G, Stefani S, Toniolo A, Rossolini GM: CTX-M-type extended-spectrum beta-lactamases in Italy: molecular epidemiology of an emerging country-wide problem. Antimicrob Agents Chemother 2006;50:2700-2706.
5. Diaz PQ, Bello HT, Dominguez MY, Trabal NF, Mella SM, Zemelman RZ, Gonzalez GR: Resistance to gentamicin, amikacin and ciprofloxacin among nosocomial isolates of Klebsiella pneumoniae subspecies producing extended spectrum beta-lactamases (in Spanish). Rev Med Chil 2004;132:1173-1178.
6. Paterson DL, Mulazimoglu L, Casellas JM, Ko WC, Goossens H, Von GA, Mohapatra S, Trenholme GM, Klugman KP, McCormack JG, Yu VL: Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum beta-lactamase production in Klebsiella pneumoniae isolates causing bacteremia. Clin Infect Dis 2000;30:473-478.
7. Knothe H, Shah P, Krcmery V, Antal M, Mitsuhashi S: Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens. Infection 1983;11:315-317.
8. Hanberger H, Garcia-Rodriguez JA, Gobernado M, Goossens H, Nilsson LE, Struelens MJ: Antibiotic susceptibility among aerobic gram-negative bacilli in intensive care units in 5 European countries. French and Portuguese ICU Study Groups. JAMA 1999;281:67-71.
9. Lewis MT, Yamaguchi K, Biedenbach DJ, Jones RN: In vitro evaluation of cefepime and other broad-spectrum beta-lactams in 22 medical centers in Japan: a phase II trial comparing two annual organism samples. The Japan Antimicrobial Resistance Study Group. Diagn Microbiol Infect Dis 1999;35:307-315.
10. National Committee for Clinical Laboratory Standards: Performance standards for antimicrobial susceptibility testing;15th informational supplement (M100-S15). Wayne, National Committee for Clinical Laboratory Standards, 2005.
11. Otman J, Cavassin ED, Perugini ME, Vidotto MC: An outbreak of extended-spectrum beta-lactamase-producing Klebsiella species in a neonatal intensive care unit in Brazil. Infect Control Hosp Epidemiol 2002;23:8-9.
12. Pfaller MA, Jones RN, Doern GV: Multicenter evaluation of the antimicrobial activity for six broad-spectrum beta-lactams in Venezuela: comparison of data from 1997 and 1998 using the Etest method. Venezuelan Antimicrobial Resistance Study Group. Diagn Microbiol Infect Dis 1999;35:153-158.
13. Sader HS, Gales AC, Granacher TD, Pfaller MA, Jones RN: Prevalence of antimicrobial resistance among respiratory tract isolates in Latin America: results from SENTRY antimicrobial surveillance program (1997-98). Braz J Infect Dis 2000;4:245-254.
14. Bell JM, Turnidge JD, Gales AC, Pfaller MA, Jones RN: Prevalence of extended spectrum beta-lactamase (ESBL)-producing clinical isolates in the Asia-Pacific region and South Africa: regional results from SENTRY Antimicrobial Surveillance Program (1998-99). Diagn Microbiol Infect Dis 2002;42:193-198.
15. Jamal W, Rotimi VO, Khodakhast F, Saleem R, Pazhoor A, Al Hashim G: Prevalence of extended-spectrum beta-lactamases in Enterobacteriaceae, Pseudomonas and tenotrophomonas as determined by the VITEK 2 and E test systems in a Kuwait teaching hospital. Med Princ Pract 2005;14:325-331.
16. Shah AA, Hasan F, Ahmed S, Hameed A: Prevalence of extended spectrum B-lactamases in nosocomial and outpatients (ambulatory). Pak J Med Sci 2004;19:187-191.
17. Luzzaro F, Mezzatesta M, Mugnaioli C, Perilli M, Stefani S, Amicosante G, Rossolini GM, Toniolo A: Trends in production of extended-spectrum beta-lactamases among Enterobacteria of medical interest: report of the second Italian nationwide survey. J Clin Microbiol 2006;44:1659-1664.
18. Dimitrov TS, Udo EE, Emara M, Awni F, Passadilla R: Etiology and antibiotic susceptibility patterns of community-acquired urinary tract infections in a Kuwait hospital. Med Princ Pract 2004;13:334-330.
19. Hageman JC, Fridkin SK, Mohammed JM, Steward CD, Gaynes RP, Tenover FC: Antimicrobial proficiency testing of National Nosocomial Infections Surveillance System hospital laboratories. Infect Control Hosp Epidemiol 2003;24:356-361.
20. Tenover FC, Mohammed MJ, Stelling J, O'Brien T, Williams R: Ability of laboratories to detect emerging antimicrobial resistance: proficiency testing and quality control results from the World Health Organization's external quality assurance system for antimicrobial susceptibility testing. J Clin Microbiol 2001;39:241-250.
21. Nordmann P, Poirel L: Emerging carbapenemases in Gram-negative aerobes. Clin Microbiol Infect 2002;8:321-331.
22. Poirel L, Nordmann P: Acquired carbapenem-hydrolyzing beta-lactamases and their genetic support. Curr Pharm Biotechnol 2002;3:117-127.
23. Poirel L, Heritier C, Spicq C, Nordmann P: In vivo acquisition of high-level resistance to imipenem in Escherichia coli. J Clin Microbiol 2004;42:3831-3833.
24. Stapleton PD, Shannon KP, French GL: Carbapenem resistance in Escherichia coli associated with plasmid-determined CMY-4 beta-lactamase production and loss of an outer membrane protein. Antimicrob Agents Chemother 1999;43:1206-1210.
25. Odeh R, Kelkar S, Hujer AM, Bonomo RA, Schreckenberger PC, Quinn JP: Broad resistance due to plasmid-mediated AmpC betalactamases in clinical isolates of Escherichia coli. Clin Infect Dis 2002;35:140-145.
26. Lartigue M-F, Poirel L, Poyart C, Réglier-Poupet H, Nordmann P: Ertapenem resistance of Escherichia coli. Emerg Infect Dis 2007;13:315-317.
27. Paterson DL: Resistance in gram-negative bacteria: Enterobacteriaceae. Am J Infect Control 2006;34:S20-S28.